Literature DB >> 34393222

[Prognostic value of preoperative platelet parameters in locally advanced renal cell carcinoma].

R T Xiao1, C Liu1, C X Xu1, W He1, L L Ma1.   

Abstract

OBJECTIVE: To explore the prognostic value of preoperative platelet parameters in locally advanced renal cell carcinoma for the risk stratification of such patients.
METHODS: Clinical data of patients with locally advanced renal cell carcinoma in the Third Hospital of Peking University from January 2015 to December 2017 were collected. The patients were divided into progression group and progression-free group according to follow-up data, and preoperative platelet parameters and clinical data between the two groups were compared. The optimal cut-off value of platelet parameters was determined by receiver operating characteristic curve (ROC) and analyzed by Kaplan-Meier survival curve. Cox proportional hazards model was used to analyze the independent risk factors of PFS. Time dependent ROC curve, net reclassification index (NRI), and integrated discrimination improvement (IDI) were used to evaluate the improvement of SSIGN model by incorporating platelet parameters.
RESULTS: Of the 215 patients, 192 (89.3%) were followed up for a median of 36 months. Sixty-four patients (29.8%) had disease progression during the follow-up, and the median PFS was 46 months. In progression group, the platelet count (PLT) was higher [(250.72 ± 88.59)×109/L vs. (227.27 ± 66.94)×109/L, P=0.042] and the platelet distribution width (PDW) was lower [(12.01 ± 2.27)% vs. (13.31 ± 2.74)%, P = 0.001] than that of progression-free groups. 285×109 /L and 12.65% as the best cut-off values of PLT and PDW, the median PFS of PLT≤285×109 /L group was significantly longer than that of PLT>285×109 /L group (53 months vs. 41 months, P=0.033), and the median PFS of PDW>12.65% group was also significantly longer than that of PDW≤12.65% group (56 months vs. 41 months, P < 0.001). Multivariate analysis showed that preoperative PDW (HR=0.735, P < 0.001), nuclear grade Ⅲ to Ⅳ (HR=2.425, P=0.001) and sarcomatoid differentiation (HR=3.101, P=0.008) were independent risk factors for PFS. The area under the curve of PDW combined with SSIGN model was larger than that with the original SSIGN model [0.748 (95%CI: 0.662-0.833) vs. 0.678 (95%CI: 0.583-0.773), P=0.193], NRI was 0.262 (P=0.04), and IDI was 0.085 (P=0.01), indicating that the predictive ability of PDW combined with SSIGN model was improved.
CONCLUSION: Preoperative high PLT and low PDW are associated with adverse prognosis of locally advanced renal cell carcinoma, and PDW is an independent risk factor. Therefore, preoperative PDW could serve as biomarker for risk stratification of locally advanced renal cell carcinoma.

Entities:  

Keywords:  Locally advanced; Platelet; Prognosis; Renal cell carcinoma

Mesh:

Year:  2021        PMID: 34393222      PMCID: PMC8365062     

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  28 in total

1.  Blood Platelet Volume Represents a Novel Prognostic Factor in Patients with Nonmetastatic Renal Cell Carcinoma and Improves the Predictive Ability of Established Prognostic Scores.

Authors:  Maximilian Seles; Florian Posch; Georg P Pichler; Thomas Gary; Karl Pummer; Richard Zigeuner; Georg C Hutterer; Martin Pichler
Journal:  J Urol       Date:  2017-07-14       Impact factor: 7.450

2.  Improved prognostication of renal cell carcinoma using an integrated staging system.

Authors:  A Zisman; A J Pantuck; F Dorey; J W Said; O Shvarts; D Quintana; B J Gitlitz; J B deKernion; R A Figlin; A S Belldegrun
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

Review 3.  Contribution of platelets to tumour metastasis.

Authors:  Laurie J Gay; Brunhilde Felding-Habermann
Journal:  Nat Rev Cancer       Date:  2011-02       Impact factor: 60.716

4.  Decreased platelet distribution width predicts a worse prognosis in patients undergoing surgical resection for hepatocellular carcinoma.

Authors:  Chen-Xi Yue; Yu-Xi Liu; Zhi-Yuan Yun; Na Li; Chang-Jiu Zhao; Rui-Tao Wang
Journal:  Cancer Biomark       Date:  2019       Impact factor: 4.388

5.  Platelet distribution width: a simple, practical and specific marker of activation of coagulation.

Authors:  E Vagdatli; E Gounari; E Lazaridou; E Katsibourlia; F Tsikopoulou; I Labrianou
Journal:  Hippokratia       Date:  2010-01       Impact factor: 0.471

6.  Elevated Platelet Count Predicts Poor Prognosis in Breast Cancer Patients with Supraclavicular Lymph Node Metastasis.

Authors:  Shaoqing Liu; Jing Fang; Dechuang Jiao; Zhenzhen Liu
Journal:  Cancer Manag Res       Date:  2020-07-20       Impact factor: 3.989

7.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Lauren C Harshman; Georg A Bjarnason; Ulka N Vaishampayan; Mary Mackenzie; Lori Wood; Frede Donskov; Min-Han Tan; Sun-Young Rha; Neeraj Agarwal; Christian Kollmannsberger; Brian I Rini; Toni K Choueiri
Journal:  Lancet Oncol       Date:  2013-01-09       Impact factor: 41.316

8.  An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score.

Authors:  Igor Frank; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Horst Zincke
Journal:  J Urol       Date:  2002-12       Impact factor: 7.450

Review 9.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.

Authors:  Holger Moch; Antonio L Cubilla; Peter A Humphrey; Victor E Reuter; Thomas M Ulbright
Journal:  Eur Urol       Date:  2016-02-28       Impact factor: 20.096

10.  Multi-institutional validation of a new renal cancer-specific survival nomogram.

Authors:  Pierre I Karakiewicz; Alberto Briganti; Felix K-H Chun; Quoc-Dien Trinh; Paul Perrotte; Vincenzo Ficarra; Luca Cindolo; Alexandre De la Taille; Jacques Tostain; Peter F A Mulders; Laurent Salomon; Richard Zigeuner; Tommaso Prayer-Galetti; Denis Chautard; Antoine Valeri; Eric Lechevallier; Jean-Luc Descotes; Herve Lang; Arnaud Mejean; Jean-Jacques Patard
Journal:  J Clin Oncol       Date:  2007-04-10       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.